Overview: Sjogrena's Syndrome Antibodies Panel
Introduction: The Sjogrena's Syndrome Antibodies Panel is a diagnostic tool designed to screen for Sjogrena's syndrome using serum samples. In India, primary Sjogrena's syndrome affects ~0.5-1 percent of adults (higher in females), causing dry eyes/mouth, fatigue, arthritis, and increased lymphoma risk. High morbidity from under-testing in rural/low-SES patients with sicca symptoms or parotid swelling, limited autoantibody labs, delayed hydroxychloroquine or artificial tears leading to corneal damage or dental caries. Per rheumatology practices aligned with ICMR and Indian Rheumatology Association guidelines, the test employs immunoassay for anti-SSA (Ro) and anti-SSB (La) over 1-2 days with high specificity (anti-SSA ~70 percent, anti-SSB ~40 percent in primary Sjogrena's), valuable for diagnosis per ACR/EULAR criteria. This diagnostic falls under autoimmune screening and targets patients with dry eyes/mouth or extraglandular features, addressing accurate detection to guide symptomatic and immunosuppressive therapy. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise Sjogrena's identification and reducing complications. Its serum-based approach ensures reliable autoantibody detection.
Other Names: Sjogren Ab Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: Anti-SSA/SSB standard in Sjogrena's criteria; in India, used in rheumatology.
Purpose: The test assesses 2 parameters including anti-SSA (Ro) to guide Sjogrena's screening, detect autoantibodies, inform therapy.
Test Parameters: 1. Anti-SSA (Ro), 2. Anti-SSB (La).
Pretest Condition: No fasting required; patients should have sicca symptoms.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on dry eyes/mouth, fatigue.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected Sjogrena's including lymphoma, benefits of screening, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive anti-SSA/SSB supports Sjogrena's diagnosis, necessitating specialist input.
Specialist Consultation: Rheumatologists should be consulted for management.
Additional Supporting Tests: Schirmer test, salivary gland biopsy for confirmation.
Test Limitations: Antibodies not present in all cases; comprehensive approach required.
References: Indian Journal of Rheumatology 2024, Autoimmune Studies India 2023.
